Subjects will receive either uproleselan (GMI-1271) or placebo (saline solution) in a blinded fashion administered together with chemotherapy. Backbone induction chemotherapy will be the investigator's choice of either MEC or FAI; the decision will be made on a subject-by-subject basis prior to randomization. Randomized subjects will receive a sentinel dose of uproleselan or placebo 24 hours prior to the first dose of chemotherapy in each treatment cycle (induction and each of up to 3 consolidation cycles), then a dose every 12 hours throughout the chemotherapy treatment and for the 2 days following the last dose of chemotherapy. Each dose of uproleselan will be a fixed dose of 800 mg. Uproleselan or placebo will be administered IV at a steady rate over a period of 20 minutes (+/-2 minutes). Backbone induction chemotherapy will be given over 5 days.
Men and women ages 18 through 75 years of age diagnosed with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy